Literature DB >> 9862372

The Qa-1b molecule binds to a large subpopulation of murine NK cells.

M Salcedo1, P Bousso, H G Ljunggren, P Kourilsky, J P Abastado.   

Abstract

Recent studies on human NK cells have demonstrated that the NK cell CD94/NKG2 receptors bind to the nonclassical MHC class I molecule HLA-E. A functional CD94/NKG2 complex has not yet been identified in rodents, but cDNA encoding rat and mouse CD94 and NKG2 have recently been cloned, suggesting that CD94/NKG2 receptors may exist in species other than man. The mouse nonclassical MHC class I molecule Qa-1 shares several features with HLA-E. This suggests that Qa-1 may be similarly recognized by murine NK cells. To study the ability of Qa-1 to bind to murine NK cells, we have produced a soluble tetrameric form of Qa-1b. In the present study, we demonstrate that Qa-1b tetramers distinctly bind to a large subset of fresh or IL-2-activated NK1.1+/CD3- splenocytes independently of the expression of Ly49 inhibitory receptors. Binding occurs whether NK cells have evolved in an MHC class I-expressing or in an MHC class I-deficient environment. Our data suggest the existence of a Qa-1-recognizing structure on a large subpopulation of murine NK cells that may be similar to the human CD94/NKG2 heterodimeric complex.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9862372     DOI: 10.1002/(SICI)1521-4141(199812)28:12<4356::AID-IMMU4356>3.0.CO;2-H

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

Review 1.  Qa-1, a nonclassical class I histocompatibility molecule with roles in innate and adaptive immunity.

Authors:  Peter E Jensen; Barbara A Sullivan; Lisa M Reed-Loisel; Dominique A Weber
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

2.  An affinity/avidity model of peripheral T cell regulation.

Authors:  Hong Jiang; Yilun Wu; Bitao Liang; Zongyu Zheng; Guomei Tang; Jean Kanellopoulos; Mark Soloski; Robert Winchester; Itamar Goldstein; Leonard Chess
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

3.  Evidence of functional Cd94 polymorphism in a free-living house mouse population.

Authors:  Linn E Knutsen; Erik Dissen; Per C Saether; Elisabeth Gyllensten Bjørnsen; Jaroslav Piálek; Anne K Storset; Preben Boysen
Journal:  Immunogenetics       Date:  2018-12-10       Impact factor: 2.846

4.  The natural killer gene complex genetic locus Chok encodes Ly-49D, a target recognition receptor that activates natural killing.

Authors:  A H Idris; H R Smith; L H Mason; J R Ortaldo; A A Scalzo; W M Yokoyama
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

5.  Implications of CD94 deficiency and monoallelic NKG2A expression for natural killer cell development and repertoire formation.

Authors:  Russell E Vance; Amanda M Jamieson; Dragana Cado; David H Raulet
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

Review 6.  Innate lymphoid cells and the MHC.

Authors:  M L Robinette; M Colonna
Journal:  HLA       Date:  2016-01       Impact factor: 4.513

7.  Recognition of the class Ib molecule Qa-1(b) by putative activating receptors CD94/NKG2C and CD94/NKG2E on mouse natural killer cells.

Authors:  R E Vance; A M Jamieson; D H Raulet
Journal:  J Exp Med       Date:  1999-12-20       Impact factor: 14.307

8.  Analysis of Qa-1(b) peptide binding specificity and the capacity of CD94/NKG2A to discriminate between Qa-1-peptide complexes.

Authors:  J R Kraft; R E Vance; J Pohl; A M Martin; D H Raulet; P E Jensen
Journal:  J Exp Med       Date:  2000-09-04       Impact factor: 14.307

9.  Nonstochastic coexpression of activation receptors on murine natural killer cells.

Authors:  H R Smith; H H Chuang; L L Wang; M Salcedo; J W Heusel; W M Yokoyama
Journal:  J Exp Med       Date:  2000-04-17       Impact factor: 14.307

10.  m144, a murine cytomegalovirus (MCMV)-encoded major histocompatibility complex class I homologue, confers tumor resistance to natural killer cell-mediated rejection.

Authors:  E Cretney; M A Degli-Esposti; E H Densley; H E Farrell; N J Davis-Poynter; M J Smyth
Journal:  J Exp Med       Date:  1999-08-02       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.